Daniel A Bizjak, Dorle Nussbaumer, Kay Winkert, Gunnar Treff, Kensuke Takabajashi, Lennart Mentz, Franziska Schober, Jasmine-Lèonike Buhl, Lucas John, Jens Dreyhaupt, Luise Steeb, Lukas C Harps, Maria K Parr, Patrick Diel, Martina Zügel, Jürgen M Steinacker
BACKGROUND: High prevalence rates of β2-agonist use among athletes in competitive sports makes it tempting to speculate that illegitimate use of β2-agonists boosts performance. However, data regarding the potential performance-enhancing effects of inhaled β2-agonists and its underlying molecular basis are scarce. METHODS: In total, 24 competitive endurance athletes (12f/12m) participated in a clinical double-blinded balanced four-way block cross-over trial to investigate single versus combined effects of β2-agonists salbutamol (SAL) and formoterol (FOR), to evaluate the potential performance enhancement of SAL (1200 µg, Cyclocaps, Pb Pharma GmbH), FOR (36 µg, Sandoz, HEXAL AG) and SAL + FOR (1200 µg + 36 µg) compared to placebo (PLA, Gelatine capsules containing lactose monohydrate, Pharmacy of the University Hospital Ulm)...
August 28, 2023: Sports Medicine—Open